Organogenesis holders back board, pay and auditor
Organogenesis Holdings Inc. reported results from its 2026 Annual Meeting of Stockholders held on June 15, 2026.
Rhea-AI Filing Summary
Organogenesis Holdings Inc. reported results from its 2026 Annual Meeting of Stockholders held on June 15, 2026. Holders of 129,564,421 shares of Class A common stock, including 38,470,359 as-converted shares from Series A Convertible Preferred Stock, were represented.
Stockholders elected nine directors, including Robert Ades and Gary S. Gillheeney, Sr., each receiving over 76 million votes for, with substantial broker non-votes reflecting street-held shares. Holders of Series A Convertible Preferred Stock also re-elected Garrett Lustig to the board by written consent.
Investors approved, on an advisory basis, the compensation of named executive officers, with 72,516,011 votes for and 12,722,258 against. They also ratified the appointment of RSM US LLP as independent registered public accounting firm for fiscal year 2026, with 128,421,160 votes for and minimal opposition.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
Series A Convertible Preferred Stock financial
broker non-votes financial
named executive officers financial
independent registered public accounting firm financial
advisory basis financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Organogenesis (ORGO) stockholders vote on at the 2026 Annual Meeting?
Were all Organogenesis (ORGO) director nominees elected at the 2026 meeting?
How did Organogenesis (ORGO) stockholders vote on executive compensation in 2026?
Which audit firm did Organogenesis (ORGO) stockholders ratify for fiscal 2026?
What role did Series A Convertible Preferred Stock holders play in Organogenesis governance?
AI-generated analysis. How Rhea-AI works. Not financial advice.